title: National Working Group Meeting on ALK diagnostics in lung cancer.
abstract: The global landscape of molecular testing is rapidly changing, with the recent publication of the International Association for the Study of Lung Cancer (IASLC)/College of American Pathologists (CAP) guidelines and the ALK Atlas. The IASLC/CAP guidelines recommend that tumors from patients with non-small cell lung cancer (NSCLC) be tested for ALK rearrangements in addition to epidermal growth factor receptor (EGFR) mutations. The spur for this recommendation is the availability of novel therapies that target these rearrangements. This article is based on coverage of a Pfizer-sponsored National Working Group Meeting on ALK Diagnostics in Lung Cancer, held around the 15th World Lung Cancer Conference, in Sydney on October 31, 2013. It is based on the presentations given by the authors at the meeting and the discussion that ensued. The content for this article was discussed and agreed on by the authors.
authors.affiliation: Tissue Pathology and Diagnostic Oncology, Royal Prince Alfred Hospital, Sydney, New South Wales, Australia; Sydney Medical School, University of Sydney, Sydney, New South Wales, Australia; School of Medicine, University of Western Sydney, Sydney, New South Wales, Australia.
authors.forename: Wendy
authors.initials: W
authors.lastname: Cooper
authors.forename: Stephen
authors.initials: S
authors.lastname: Fox
authors.forename: Sandra
authors.initials: S
authors.lastname: O'Toole
authors.forename: Adrienne
authors.initials: A
authors.lastname: Morey
authors.forename: Glenn
authors.initials: G
authors.lastname: Frances
authors.forename: Nick
authors.initials: N
authors.lastname: Pavlakis
authors.forename: Kenneth
authors.initials: K
authors.lastname: O'Byrne
authors.forename: Andrew
authors.initials: A
authors.lastname: Dettrick
authors.forename: Trishe
authors.initials: T
authors.lastname: Leong
authors.forename: Vivek
authors.initials: V
authors.lastname: Rathi
authors.forename: Dominic
authors.initials: D
authors.lastname: Spagnolo
authors.forename: Chris
authors.initials: C
authors.lastname: Hemmings
authors.forename: Mahendra
authors.initials: M
authors.lastname: Singh
authors.forename: David
authors.initials: D
authors.lastname: Moffat
authors.forename: Ming-Sound
authors.initials: MS
authors.lastname: Tsao
authors.forename: Keith
authors.initials: K
authors.lastname: Wilner
authors.forename: Richard
authors.initials: R
authors.lastname: Buller
authors.forename: Susan
authors.initials: S
authors.lastname: Pitman Lowenthal
authors.forename: Shams
authors.initials: S
authors.lastname: Arifeen
authors.forename: Justin
authors.initials: J
authors.lastname: Binko
authors.forename: Mahmood
authors.initials: M
authors.lastname: Alam
mesh_terms: D000077548:Anaplastic Lymphoma Kinase; D002289:Carcinoma, Non-Small-Cell Lung / Q000737:chemistry / Q000175:diagnosis* / Q000235:genetics; D003226:Congresses as Topic; D006801:Humans; D008175:Lung Neoplasms / Q000737:chemistry / Q000175:diagnosis* / Q000235:genetics; D009154:Mutation; D017410:Practice Guidelines as Topic; D020794:Receptor Protein-Tyrosine Kinases / Q000032:analysis* / Q000235:genetics
chemical_list: C000626173:ALK protein, human; D000077548:Anaplastic Lymphoma Kinase; D020794:Receptor Protein-Tyrosine Kinases
keywords: ALK testing; fluorescence in situ hybridization; immunohistochemistry; molecular diagnostics; nonsmall cell lung cancer